Differences in immune responses between cmv-seronegative and-seropositive patients with myocardial ischemia and reperfusion

Immunity, Inflammation and Disease

Volumn 3, Issue 2, 2015, Pages 56-70

  Shmeleva, Evgeniya V ^a   Boag, Stephen E ^a   Murali, Santosh ^a,b   Bennaceur, Karim ^a   Das, Rajiv ^a,c   Egred, Mohaned ^a,c   Purcell, Ian ^c   Edwards, Richard ^c   Todryk, Stephen ^a,b   Spyridopoulos, Ioakim ^a,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NORTHUMBRIA UNIVERSITY   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

CMV infection; Cytokines; Myocardial infarction; Reperfusion injury; T cells

Indexed keywords

EID: 85013393940     PISSN: None     EISSN: 20504527     Source Type: Journal    
DOI: 10.1002/iid3.49     Document Type: Article

References (47)

1. Ludman, P. F. 2013. BCIS audit returns adult interventional procedures January 2012 to December 2012. http://www.bcis. org.uk/resources/BCIS_Audit_2012_for_web_V2_14–10-20131.pdf
2. Velagaleti, R. S., M. J. Pencina, JM. Murabito, T. J. Wang, N. I. Parikh, R. B. D’Agostino, D. Levy, W. B. Kannel and R. S. Vasan. 2008. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 118:2057– 2062.
3. Khan, N., N. Shariff, M. Cobbold, R. Bruton, J. A. Ainsworth, A. J. Sinclair, L. Nayak, and P. A. Moss. 2002. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J. Immunol. 169:1984–1992.
4. Kuijpers, T. W. M. T. Vossen, M. R. Gent, J. C. Davin, M. T. Roos, P. M. Wertheim-van Dillen, JF. Weel, P. A. Baars, and R. A. van Lier. 2003. Frequencies of circulating cytolytic, CD45RA+CD27-, CD8+ T lymphocytes depend on infection with CMV. J. Immunol. 170:4342–4348.
5. Savva, G. M., A. Pachnio, B. Kaul, K. Morgan, F. A. Huppert, C. Brayne, and P. A. Moss. 2013. Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell. 12:381–387.
6. Hoffmann, J., E. Shmeleva, S. E. Boag, K. Fiser, A. Bagnall, S. Murali, I. Dimmick, H. Pircher, C. Martin-Ruiz, M. Egred, et al. 2015. Myocardial ischemia and reperfusion leads to transient CD8 immune deficiency and accelerated immuno-senescence in CMV-seropositive patients. Circ. Res 116:87–98.
7. Spyridopoulos, I., J. Hoffmann, A. Aicher, T. H. Brummen-dorf, HW Doerr, A. M. Zeiher, and S. Dimmeler. 2009. Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity. Circulation 120:1364–1372.
8. Hoffmann, J., K. Fiser, J. Weaver, I. Dimmick, M. Loeher, H. Pircher, C. Martin-Ruiz, M. Veerasamy, B. Keavney, T. von Zglinicki, et al. 2012. High-throughput 13-parameter immunophenotyping identifies shifts in the circulating T-cell compartment following reperfusion in patients with acute myocardial infarction. PLoS ONE 7:e47155.
9. Todryk S. M., A. A. Pathan, S. Keating, D. W. Porter, T. Berthoud, F. Thompson, P. Klenerman, and A. V. Hill. 2009. The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology 128:83–91.
10. Currier, J. R., E. G. Kuta, E. Turk, L. B. Earhart, L. Loomis-Price, S. Janetzki, G. Ferrari, D. L. Birx, and J. H. Cox. 2002. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260:157–172.
11. Derhovanessian, E., A. B. Maier, K. Hahnel, H. Zelba, A. J. de Craen, H. Roelofs, E. P. Slagboom, R. G. Westendorp, and G. Pawelec. 2013. Lower proportion of naive peripheral CD8+ T cells and an unopposed pro-inflammatory response to human Cytomegalovirus proteins in vitro are associated with longer survival in very elderly people. Age (Dordr). 35:1387–1399.
12. Rizzo, L. B., C. H. Do Prado, R. Grassi-Oliveira, A. Wieck, BL. Correa, A. L. Teixeira, and M. E. Bauer. 2013. Immunose-nescence is associated with human cytomegalovirus and shortened telomeres in type I bipolar disorder. Bipolar Disord. 15:832–838.
13. Nunez, J. E. Nunez, V. Bodi, J. Sanchis, G. Minana, L. Mainar, E. Santas, P. Merlos, E. Rumiz, H. Darmofal, et al. 2008. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am. J. Cardiol. 101:747–752.
14. Mocchegiani, E., R. Giacconi, C. Cipriano, and M. Malavolta. 2009. NK and NKT cells in aging and longevity: role of zinc and metallothioneins. J. Clin. Immunol. 29:416–425.
15. Strioga, M., V. Pasukoniene, and D. Characiejus. 2011. CD8+ CD28-and CD8+ CD57+ T cells and their role in health and disease. Immunology 134:17–32.
16. Schwartz, R. H., 2003. T cell anergy. Annu. Rev. Immunol. 21:305–334.
17. Vigano, S., M. Perreau, G. Pantaleo, and A. Harari. 2012. Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin. Dev. Immunol. 2012:485781.
18. Yap, M., F. Boeffard, E. Clave, A. Pallier, R. Danger, M. Giral, J. Dantal, Y. Foucher, C. Guillot-Gueguen, A. Toubert, et al. 2014. Expansion of highly differentiated cytotoxic terminally differentiated effector memory CD8+ T cells in a subset of clinically stable kidney transplant recipients: a potential marker for late graft dysfunction. J. Am. Soc. Nephrol. 25:1856–1868.
19. Cruikshank, W. W., H. Kornfeld, and D. M. Center. 2000. Interleukin-16. J. Leukoc. Biol. 67:757–766.
20. Kaser A., S. Dunzendorfer, F. A. Offner, T. Ryan, A. Schwabegger, W. W. Cruikshank, C. J. Wiedermann, and H. Tilg. 1999. A role for IL-16 in the cross-talk between dendritic cells and T cells. J. Immunol. 163:3232–3238.
21. McFadden, C., R. Morgan, S. Rahangdale, D. Green, H. Yamasaki, D. Center, and W. Cruikshank. 2007. Preferential migration of T regulatory cells induced by IL-16. J. Immunol. 179:6439–6445.
22. Theodore, A. C., D. M. Center, J. Nicoll, G. Fine, H. Kornfeld, and W. W. Cruikshank. 1996. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J. Immunol. 157:1958–1964.
23. De Bie, J. J., E. H. Jonker, P. A. Henricks, J. Hoevenaars, F. F. Little, W. W. Cruikshank, F. P. Nijkamp, and A. J. Van Oosterhout. 2002. Exogenous interleukin-16 inhibits anti-gen-induced airway hyper-reactivity, eosinophilia and Th2-type cytokine production in mice. Clin. Exp. Allergy 32:1651– 1658.
24. Klimiuk, P. A., J. J. Goronzy, and C. M. Weyand. 1999. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J. Immunol. 162:4293–4299.
25. Glass, W. G., R. T. Sarisky, and A. M. Vecchio. 2006. Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J. Interferon Cytokine Res. 26:511–520.
26. Yan, X., A. Anzai, Y. Katsumata, T. Matsuhashi, K. Ito, J. Endo, T. Yamamoto, A. Takeshima, K. Shinmura, W. Shen, et al. 2013. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J. Mol. Cell. Cardiol. 62:24–35.
27. Mason, D., 1998. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19:395–404.
28. D’Orsogna, L. J., D. L. Roelen, I. I. Doxiadis, and F. H. Claas. 2010. Alloreactivity from human viral specific memory T-cells. Transpl. Immunol. 23:149–155.
29. Broux, B., K. Pannemans, X Zhang, S. Markovic-Plese, T. Broekmans, BO. Eijnde, B. Van Wijmeersch, V. Somers, P. Geusens S. van der Pol, et al. 2012. CX(3)CR1 drives cytotoxic CD4(+)CD28( ) T cells into the brain of multiple sclerosis patients. J. Autoimmun. 38:10–19.
30. Thewissen, M., V. Somers, K. Venken, L. Linsen, P. van Paassen, P. Geusens, J. Damoiseaux, and P. Stinissen. 2007. Analyses of immunosenescent markers in patients with autoimmune disease. Clin. Immunol. 123:209–218.
31. Zal, B., J. C. Kaski, G. Arno, J. P. Akiyu, Q. Xu, D. Cole, M. Whelan, N. Russell, J. A. Madrigal, I. A. Dodi, et al. 2004. Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation 109:1230–1235.
32. Antonelli, A., S. M. Ferrari, D. Giuggioli, E. Ferrannini, C. Ferri, and P. Fallahi. 2014. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev. 13:272–280.
33. Lee, E. Y., Z. H. Lee, and Y. W. Song. 2009. CXCL10 and autoimmune diseases. Autoimmun. Rev. 8:379–383.
34. Qin, S., J. B. Rottman, P. Myers, N. Kassam, M. Weinblatt, M. Loetscher, A. E. Koch, B. Moser, and C. R. Mackay. 1998. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101:746–754.
35. Baggiolini, M., B. Dewald, and B. Moser. 1997. Human chemokines: an update. Annu. Rev. Immunol. 15:675–705.
36. Heller, E. A., E. Liu, A. M. Tager, Q. Yuan, AY. Lin, N. Ahluwalia, K. Jones, S. L. Koehn, VM. Lok, E. Aikawa, et al. 2006. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 113:2301–2312.
37. Westman, G., D. Berglund, J. Widen, M. Ingelsson, O. Korsgren, L. Lannfelt, D. Sehlin, A. K. Lidehall, and B. M. Eriksson. 2014. Increased inflammatory response in cytomegalovirus seropositive patients with Alzheimer’s disease. PLoS ONE 9:e96779.
38. Madan, R., F. Demircik, S. Surianarayanan, J. L. Allen, S. Divanovic, A. Trompette, N. Yogev, Y. Gu, M. Khodoun, D. Hildeman, et al. 2009. Nonredundant roles for B cell-derived IL-10 in immune counter-regulation. J. Immunol. 183:2312–2320.
39. Mege, J. L., S. Meghari, A. Honstettre, C. Capo, and D. Raoult. 2006. The two faces of interleukin 10 in human infectious diseases. Lancet Infect. Dis. 6:557–569.
40. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O’Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683–765.
41. Emmerich, J., J. B. Mumm, I. H. Chan, D. LaFace, H. Truong, T. McClanahan D. M. Gorman, and M. Oft. 2012. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 72:3570–3581.
42. Mumm, J. B., and M. Oft. 2013. Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-gamma-mediated CD8(+) T cell cytotoxicity. Bioessays 35:623–631.
43. Lauw, F. N., D. Pajkrt, C. E. Hack, M. Kurimoto, S. J. van Deventer, and T. van der Poll. 2000. Proinflammatory effects of IL-10 during human endotoxemia. J. Immunol. 165:2783–2789.
44. Mocellin, S., M. Panelli, E. Wang, C. R. Rossi, P. Pilati, D. Nitti, M. Lise, and F. M. Marincola. 2004. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun. 5:621–630.
45. Akdis, C. A., and K. Blaser. 2001. Mechanisms of interleukin-10-mediated immune suppression. Immunology 103:131– 136.
46. Mocellin, S., F. Marincola, C. R. Rossi, D. Nitti, and M. Lise. 2004. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev. 15:61–76.
47. Vora, M., L. I. Romero, and M. A. Karasek. 1996. Interleukin-10 induces E-selectin on small and large blood vessel endothelial cells. J. Exp. Med. 184:821–829.